valu usd unless otherwis note
set offens look past near-term
headwind upgrad outperform
view upgrad outperform add offens
posit list expect see greater impact
peer consensu still high share reflect
look past near-term headwind see ep step-up
trough valuat drive share immin deal close like
re-affirmed dividend add near-term support rais pt
model revisit link mark recent bottom
share drg sinc weve like risk/reward link
also miss opportun upgrad earlierwer
still under-perform sinc relat downturn
vs drg want get front result expect
dividend re-affirmed clariti improv expect
ep guidanc move lower year also see step-up/rebound
come trough valuat want get ahead
market ultim shift defens offens posit
like see greater impact peer consensu
slow move focu quickli shift beyond
transit year expect close soon relat
impact continu summer year messi could creat
stock disrupt step normal
earn rel quick bounce-back around core franchis
recent check core franchis encourag
becom hard ignor immun pressur
expect across space continu link recent color core
franchis favor includ imbruvica link past downturn
rebound aesthet link strength survey feedback skyrizi
link collect pro-forma revenu
expect reaffirm sector-high dividend
dividend increas per exhibit expect
re-affirmed report send favor messag
pro-forma valuat near histor low get past close
could catalyst valuat argument new recent rel
under-perform pharma near-trough price-to-earnings approach
drawn-out close could offer upsid support
growth post humira still unclear biggest question us around
valuat potenti still host concern
ultim need address becom harder us
valuat argu that bake stock neg impli
termin growth post leav option around
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
bloomberg capit market estim upside/downside/target
base case see price target impli price-to-earnings
pro-forma ep
assum may deal close allergan
specif addit accret built estim
expect continu annual busi develop
strong uptak key growth product skyrizi
assum slowdown
econom downturn
upsid case scenario see price target impli
price-to-earnings pro-forma ep
invest thesi base view
abb gener double-digit near-term growth growth
back catch-up strength core
franchis continu long-term question post
us humira loss exclus loe see dividend
support synergy-driven support next three
year thesi base follow key point
support sector perform rate
see greater impact street around
expect catch-up signific
support robust growth biggest concern around
aesthet franchis compris
pro-forma revenu follow immunolog slow-down
check suggest bounc back meaning
long-term growth stori still unclear valuat
price littl humira goe biosimilar
see pressur out-year earn time
next year balanc sheet focu
reposit long-term growth also see option
around spin ipo acquir medic aesthet
believ highest dividend lowest
valuat could support share see upsid
potenti offens post recoveri
trade close histor low see cash flow support
current sector-high dividend help support
share anticip recoveri
faster uptak key growth product skyrizi
assum deal close allergan addit
accret built estim
lower humira eros follow us loss exclus
quicker clear relat pandem
potenti catalyst close allergan acquisit may
sever data read focu rinvoq ph data
atop derm skyrizi motiv data
cd induct bi voltaire-x interchang studi
read-out biosimilar humira head-to-head calquence/
imbruvica data r/r cll
downsid case scenario see price target
impli price-to-earnings downsid pro-forma ep
sluggish uptak key growth product skyrizi
assum prolong deal closur allergan and/or
stringent ftc divestitur requir expect
aggress humira eros follow us loss
exclus expect
greater impact expect
risk thesi delay close allergan deal
competit risk particularli around hem-onc franchis
botox slower uptak key grower greater
expect impact
near histor low below-street pro-forma ep two key chart
exhibit share near-term all-tim low pro-forma ep
exhibit expect reaffirm current dividend may earn still remain well peer yield
avgdrgdrg avgxabbv near histor low pro-forma ep street p/emov higher follow june deal announcementweakesson humira biosimilar concern abbvi inc
target driven larg pharma framework pro-forma forecast
left forecast unchang remain well consensu price
target methodolog reflect pro-forma estim includ well ensu
capit structur made minor chang adjust factor reflect
rel growth risk next three year impli multipl still
materi peer pro-forma forecast model exhibit abbvi
stand-alone exhibit
exhibit made adjust price target framework still adjust impli valuat target well
peer host factor
p/eev/ebitda averagem track recorddividend yieldgrowth profilelo risk p/eev/ebitdashar cap net debtenterpris valueshar estimate net leverageimpliedotherpriceimplieddebt adj target adjust price target repres addit valu attribut plan newco spin captur pro-forma estim note adjust price target repres addit valu relat myl/viatri contribut captur estim averageadjust factor /- forecast total exhibit street pro-forma ep deal growth expect double-digit strateg
move support post-humira biosimilar impact still need
forma incom stand-alon modellegaci stand-alon modelless net product zenpep contributiongross profit cost synergi year oper incom expens foreign exchang incom expens interest expens incom tax tax earn ep share share per rate legaci legaci net profit analysi share per exhibit
 incom guid appr op growth product profit guid guid guid salesoper incom guid sale expens guid billionnet foreign exchang incom expens interest expens incom tax tax guid adjust tax rate earn ep guid share share guid flatdividend per increas announc yield price dividend yield assum annual increasesebitda guid guid guid salesoper guid sale guid profit analysi guid appr op growth share per inc
price target base equal ev/ebitda price-to-earnings estim reflect
close allergan acquisit use multipl respect
reflect meaning discount histor industri averag adjust us loss
exclus humira impli return price target support outperform
risk rate price target
risk rate price target includ limit tail valu risk
humira still meaning contributor combin compani acquisit risk work
close integr allergan transact largest deal histori
regulatory/polit risk broadli applic sector particularli around pricing/
global biopharmaceut compani base chicago il spun
abbott becam independ publicly-trad compani compani
track record acquisit pharmacycl stemcentrx
announc acquisit allergan expect close upon
close allergan transact combin compani focus immunolog
hematolog oncolog medic aesthet neurosci franchis
